These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 35218966)
1. A global survey in the developmental landscape of possible vaccination strategies for COVID-19. Gasmi A; Srinath S; Dadar M; Pivina L; Menzel A; Benahmed AG; Chirumbolo S; Bjørklund G Clin Immunol; 2022 Apr; 237():108958. PubMed ID: 35218966 [TBL] [Abstract][Full Text] [Related]
2. Vaccination is the most effective and best way to avoid the disease of COVID-19. Lotfi H; Mazar MG; Ei NMH; Fahim M; Yazdi NS Immun Inflamm Dis; 2023 Aug; 11(8):e946. PubMed ID: 37647441 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885 [TBL] [Abstract][Full Text] [Related]
6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
7. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
11. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Francis AI; Ghany S; Gilkes T; Umakanthan S Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438 [TBL] [Abstract][Full Text] [Related]
12. [COVID-19 infections and effectiveness of the vaccination among healthcare workers]. Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547 [TBL] [Abstract][Full Text] [Related]
13. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678 [TBL] [Abstract][Full Text] [Related]
15. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
16. The impact of geo-political socio-economic factors on vaccine dissemination trends: a case-study on COVID-19 vaccination strategies. Chauhan R; Varma G; Yafi E; Zuhairi MF BMC Public Health; 2023 Nov; 23(1):2142. PubMed ID: 37919737 [TBL] [Abstract][Full Text] [Related]
17. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
18. Development of an Inactivated Vaccine against SARS CoV-2. Pavel STI; Yetiskin H; Uygut MA; Aslan AF; Aydın G; İnan Ö; Kaplan B; Ozdarendeli A Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835197 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024 [TBL] [Abstract][Full Text] [Related]
20. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]